Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

NCT06408623 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: chidamide combined with Sintilimab and bevacizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences